A Granelli-Piperno1, V Finkel, E Delgado, R M Steinman. 1. Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York 10021-6399, USA. piperno@rockvax.rockefeller.edu
Abstract
BACKGROUND: To initiate immunity, dendritic cells (DCs) capture antigens or viruses at body surfaces, undergo maturation to express T-cell costimulatory molecules, and then migrate to lymphoid organs. DCs at body surfaces can capture human immunodeficiency virus 1 (HIV-1), but mature DCs do not support replication of the virus unless T cells are added. The initial site for HIV-1 replication remains unknown and it is unclear whether replication can take place in DCs or whether the virus must first be transmitted from DCs to T cells. RESULTS: We generated mature DCs from monocyte precursors. Upon infection with HIV-1, reverse transcription was completed only when T cells were added. When the reverse transcriptase inhibitor azidothymidine was added to the DCs during exposure to HIV-1, the DCs remained fully infectious, as long as the drug was removed just before culturing the DCs with T cells. HIV-1 variants that were engineered to undergo only one cycle of replication were able to infect DCs and replicate once in these cells. When T cells were added, newly produced HIV-1 Gag protein was exclusively localized to the DCs. With wild-type virus, subsequent rounds of replication took place in T cells. Soluble CD40 ligand (CD40L) and CD40L-transfected fibroblasts stimulated HIV-1 replication in purified mature DCs. CONCLUSIONS: Mature DCs provide a drug-resistant reservoir for HIV-1. This reservoir is activated within DCs by CD40L and upon interaction with T cells, and the virus then spreads rapidly to other T cells.
BACKGROUND: To initiate immunity, dendritic cells (DCs) capture antigens or viruses at body surfaces, undergo maturation to express T-cell costimulatory molecules, and then migrate to lymphoid organs. DCs at body surfaces can capture human immunodeficiency virus 1 (HIV-1), but mature DCs do not support replication of the virus unless T cells are added. The initial site for HIV-1 replication remains unknown and it is unclear whether replication can take place in DCs or whether the virus must first be transmitted from DCs to T cells. RESULTS: We generated mature DCs from monocyte precursors. Upon infection with HIV-1, reverse transcription was completed only when T cells were added. When the reverse transcriptase inhibitor azidothymidine was added to the DCs during exposure to HIV-1, the DCs remained fully infectious, as long as the drug was removed just before culturing the DCs with T cells. HIV-1 variants that were engineered to undergo only one cycle of replication were able to infect DCs and replicate once in these cells. When T cells were added, newly produced HIV-1Gag protein was exclusively localized to the DCs. With wild-type virus, subsequent rounds of replication took place in T cells. Soluble CD40 ligand (CD40L) and CD40L-transfected fibroblasts stimulated HIV-1 replication in purified mature DCs. CONCLUSIONS: Mature DCs provide a drug-resistant reservoir for HIV-1. This reservoir is activated within DCs by CD40L and upon interaction with T cells, and the virus then spreads rapidly to other T cells.
Authors: Li Wu; Arman A Bashirova; Thomas D Martin; Loreley Villamide; Erin Mehlhop; Andrei O Chertov; Derya Unutmaz; Melissa Pope; Mary Carrington; Vineet N KewalRamani Journal: Proc Natl Acad Sci U S A Date: 2002-01-29 Impact factor: 11.205
Authors: Gabriele Pollara; Antonia Kwan; Philippa J Newton; Matthew E Handley; Benjamin M Chain; David R Katz Journal: Int J Exp Pathol Date: 2005-08 Impact factor: 1.925
Authors: Klara Tenner-Racz; Christiane Stahl Hennig; Klaus Uberla; Heribert Stoiber; Ralf Ignatius; Jonathan Heeney; Ralph M Steinman; Paul Racz Journal: Proc Natl Acad Sci U S A Date: 2004-02-17 Impact factor: 11.205
Authors: Jessie-F Fecteau; Laura G Corral; Emanuela M Ghia; Svetlana Gaidarova; Diahnn Futalan; Ila Sri Bharati; Brian Cathers; Maria Schwaederlé; Bing Cui; Antonia Lopez-Girona; Davorka Messmer; Thomas J Kipps Journal: Blood Date: 2014-07-02 Impact factor: 22.113